Citations

Mayo Clinic

Clear

4796 citation(s) found for "Yu, Jennifer".

A Novel Socioeconomic Measure Using Individual Housing Data in Cardiovascular Outcome Research
Bang, Duk Won , Manemann, Sheila M., Gerber, Yariv , Roger, Véronique L. , Lohse, Christine M. , Rand-Weaver, Jennifer, Yawn, Barbara, Juhn, Young J. , Krusemark, Elizabeth, Krusemark, Elizabeth A. , Yawn, Barbara P.

International Journal of Environmental Research and Public Health | November 12, 2014 | Volume: 11 | Issue: 11 | Pages: 11597-11615

10.3390/ijerph111111597 | PMID 25396769 Get It

Background: To assess whether the individual housing-based socioeconomic status (SES) measure termed HOUSES was associated with post-myocardial infarction (MI) mortality. Methods: The study was designed as a population-based cohort study, which compared post-MI mortality among Olmsted County, Minnesota, USA, residents with different SES as measured by HOUSES using Cox proportional hazards models. Subjects’ addresses at index date of MI were geocoded to real property data to formulate HOUSES (a z-score for housing value, square footage, and numbers of bedrooms and bathrooms). Educational levels were used as a comparison for the HOUSES index. Results: 637 of the 696 eligible patients with MI (92%) were successfully geocoded to real property data. Post-MI survival rates were 60% (50–72), 78% (71–85), 72% (60–87), and 87% (81–93) at 2 years for patients in the first (the lowest SES), second, third, and fourth quartiles of HOUSES, respectively (p < 0.001). HOUSES was associated with post-MI all-cause mortality, controlling for all variables except age and comorbidity (p = 0.036) but was not significant after adjusting for age and comorbidity (p = 0.24). Conclusions: Although HOUSES is associated with post-MI mortality, the differential mortality rates by HOUSES were primarily accounted for by age and comorbid conditions. HOUSES may be useful for health disparities research concerning cardiovascular outcomes, especially in overcoming the paucity of conventional SES measures in commonly used datasets.
Perspectives from the American Society of Clinical Oncology 2014 Conference: Breast Cancer Highlights
Crozier, Jennifer A. , Perez, Edith A., Perez, Edith A.

Future Oncology | November 11, 2014 | Volume: 10 | Issue: 12 | Pages: 1897-1899

10.2217/fon.14.151 | PMID 25386807 Get It

Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria
Berini, Sarah E. , Tracy, Jennifer A., Engelstad, JaNean , Lorenz, Elizabeth C. , Milliner, Dawn S. , Dyck, P. James B.

Muscle & Nerve | October 31, 2014 | Volume: 51 | Issue: 3 | Pages: 449-454

10.1002/mus.24495 | PMID 25363903 Get It

ABSTRACTIntroduction: A 24‐year‐old man with primary hyperoxaluria type 1 (PH1) presented with a rapidly progressive axonal and demyelinating sensorimotor polyradiculoneuropathy shortly after the onset of end‐stage renal disease. His plasma oxalate level was markedly elevated at 107 µmol/L (normal <1.8 µmol/L). Methods: A sural nerve biopsy was performed. Teased fiber and paraffin and epoxy sections were done and morphometric procedures were performed on this sample and on an archived sample from a 22‐year‐old man as an age‐ and gender‐matched control. Embedded teased fiber electron microscopy was also performed. Results: The biopsy revealed secondary demyelination and axonal degeneration. Under polarized light, multiple bright hexagonal, rectangular, and starburst inclusions, typical of calcium oxalate monohydrate crystals, were seen. Conclusions: The proposed mechanisms of nerve damage include disruption of axonal transport due to crystal deposition, toxic effect of oxalate, or nerve ischemia related to vessel occlusion from oxalate crystal deposition. Muscle Nerve 51: 449–454, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data
Tang, Xiaojia , Baheti, Saurabh , Thompson, Kevin J. , Wills, Quin F., Niu, Nifang, Holcomb, Ilona N., Boutet, Stéphane C., Ramakrishnan, Ramesh, Kachergus, Jennifer M., Kocher, Jean‐Pierre , Weinshilboum, Richard M. , Wang, Liewei , Thompson, E Aubrey, Kalari, Krishna R. , Shameer, Khader, Wills, Quin, Shameer, Khader , Weinshilboum, Richard M. , Thompson, Kevin J , Kalari, Krishna R , Tang, Xiaojia

Nucleic Acids Research | October 29, 2014 | Volume: 42 | Issue: 22 | Pages: e172-e172

10.1093/nar/gku1005 | PMID 25352556 Get It

Abstract Rapid development of next generation sequencing technology has enabled the identification of genomic alterations from short sequencing reads. There are a number of software pipelines available for calling single nucleotide variants from genomic DNA but, no comprehensive pipelines to identify, annotate and prioritize expressed SNVs (eSNVs) from non-directional paired-end RNA-Seq data. We have developed the eSNV-Detect, a novel computational system, which utilizes data from multiple aligners to call, even at low read depths, and rank variants from RNA-Seq. Multi-platform comparisons with the eSNV-Detect variant candidates were performed. The method was first applied to RNA-Seq from a lymphoblastoid cell-line, achieving 99.7% precision and 91.0% sensitivity in the expressed SNPs for the matching HumanOmni2.5 BeadChip data. Comparison of RNA-Seq eSNV candidates from 25 ER+ breast tumors from The Cancer Genome Atlas (TCGA) project with whole exome coding data showed 90.6–96.8% precision and 91.6–95.7% sensitivity. Contrasting single-cell mRNA-Seq variants with matching traditional multicellular RNA-Seq data for the MD-MB231 breast cancer cell-line delineated variant heterogeneity among the single-cells. Further, Sanger sequencing validation was performed for an ER+ breast tumor with paired normal adjacent tissue validating 29 out of 31 candidate eSNVs. The source code and user manuals of the eSNV-Detect pipeline for Sun Grid Engine and virtual machine are available at http://bioinformaticstools.mayo.edu/research/esnv-detect/.
Biological Strategies for Improved Osseointegration and Osteoinduction of Porous Metal Orthopedic Implants
Lewallen, Eric A. , Riester, Scott M. , Kremers, Hilal Maradit , Dudakovic, Amel , Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Lewallen, Eric Alexander, Bonin, Carolina A. , Kakar, Sanjeev , Westendorf, Jennifer J. , van Wijnen, Andre J , Maradit Kremers, Hilal

Tissue Engineering Part B: Reviews | October 27, 2014 | Volume: 21 | Issue: 2 | Pages: 218-230

10.1089/ten.teb.2014.0333 | PMID 25348836 Get It

The biological interface between an orthopedic implant and the surrounding host tissue may have a dramatic effect upon clinical outcome. Desired effects include bony ingrowth (osseointegration), stimulation of osteogenesis (osteoinduction), increased vascularization, and improved mechanical stability. Implant loosening, fibrous encapsulation, corrosion, infection, and inflammation, as well as physical mismatch may have deleterious clinical effects. This is particularly true of implants used in the reconstruction of load-bearing synovial joints such as the knee, hip, and the shoulder. The surfaces of orthopedic implants have evolved from solid-smooth to roughened-coarse and most recently, to porous in an effort to create a three-dimensional architecture for bone apposition and osseointegration. Total joint surgeries are increasingly performed in younger individuals with a longer life expectancy, and therefore, the postimplantation lifespan of devices must increase commensurately. This review discusses advancements in biomaterials science and cell-based therapies that may further improve orthopedic success rates. We focus on material and biological properties of orthopedic implants fabricated from porous metal and highlight some relevant developments in stem-cell research. We posit that the ideal primary and revision orthopedic load-bearing metal implants are highly porous and may be chemically modified to induce stem cell growth and osteogenic differentiation, while minimizing inflammation and infection. We conclude that integration of new biological, chemical, and mechanical methods is likely to yield more effective strategies to control and modify the implant–bone interface and thereby improve long-term clinical outcomes.
Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project
Ringold, Sarah , Hendrickson, Audrey, Abramson, Leslie, Beukelman, Timothy , Blier, Peter R., Bohnsack, John F. , Chalom, Elizabeth, Gewanter, Harry L., Gottlieb, Beth S. , Hollister, Roger, Hsu, Joyce , Hudgins, Andrea, Klein‐Gitelman, Marisa, Lindsley, Carol B., Lopez‐Benitez, Jorge M. , Lovell, Daniel J. , Mason, Tom, Milojevic, Diana , Moorthy, Lakshmi N., Nanda, Kabita , Onel, Karen , Rabinovich, C. Egla, Ray, Linda, Rouster‐Stevens, Kelly , Ruth, Natasha M. , Shishov, Michael , Spalding, Steven J., Syed, Reema , Vehe, Richard K. , Weiss, Jennifer E. , White, Andrew J. , Wallace, Carol A., Sobel, Rachel E. , Ilowite, Norman T. , Moorthy, L. Nandini , Prahalad, Sampath , Stoll, Matthew Laurence , White, Andrew J

Arthritis Care & Research | October 20, 2014 | Volume: 67 | Issue: 4 | Pages: 529-537

10.1002/acr.22487 | PMID 25331530 Get It

ObjectiveFew data are available regarding the rates of serious adverse events (SAEs) and important medical events (IMEs) outside of product‐based registries and clinical trials for juvenile idiopathic arthritis (JIA). The Enhanced Drug Safety Surveillance Project (EDSSP) was developed to pilot a novel system to collect SAEs/IMEs in children with JIA. This analysis reports the results from this 4‐year (2008–2012) EDSSP.MethodsParticipating physicians were surveyed monthly to ascertain whether their JIA patients experienced an SAE or IME. Sites were surveyed every 6 months to determine the number of unique JIA patients seen at each site during that 6‐month period. Reporting rates were calculated per 100 person‐years and 95% confidence intervals (95% CIs) were calculated based on a Poisson distribution.ResultsThirty‐seven Childhood Arthritis and Rheumatology Research Alliance sites with 115 physicians participated. The mean response rate to the monthly surveys was 65%. There were 147 total SAEs and 145 total IMEs. The largest proportion of SAEs and IMEs occurred in children with polyarticular JIA (39% and 37%, respectively). The majority of SAEs and IMEs were reported for patients receiving therapy with biologic agents (76% and 69%, respectively). The total event rate for SAEs and IMEs combined was 1.07 events per 100 person‐years (95% CI 0.95–1.19). The rates for SAEs and IMEs were 0.54 per 100 person‐years (95% CI 0.45–0.63) and 0.53 per 100 person‐years (95% CI 0.49–0.62), respectively.ConclusionThe EDSSP provided a simple tool for SAE/IME reporting within an established research network and resulted in a similar range of reported events as captured by a traditional product‐based registry.
Chronic urticarial eruption associated with monoclonal gammopathy
Barbosa, Naiara S. , Schoch, Jennifer J. , Ringler, Michael D. , Wetter, David A.

American Journal of Hematology | October 20, 2014 | Volume: 90 | Issue: 4 | Pages: 365-366

10.1002/ajh.23873 | PMID 25329746 Get It

Genomic Data in the Electronic Medical Record
Kimball, Brittany , Nowakowski, K, Maschke, Karen J. , Kimball, Brittany C, Nowakowski, Katherine E, McCormick, Jennifer B, McCormick, Jennifer Blair , Kimball, Brittany C

Journal of Empirical Research on Human Research Ethics | October 14, 2014 | Volume: 9 | Issue: 5 | Pages: 16-24

10.1177/1556264614553922 | PMID 25747687 Get It

A proof of principle pharmacogenomic translational study was used as a case example to explore Biobank Community Advisory Board (CAB) member views about placing genomic information into the medical record and to establish how CAB input could affect research design. CAB members expressed enthusiasm for the potential benefit of the research discussed, yet voiced concerns regarding the recruitment and consent materials. They discussed the value of genomic research and its clinical utility; the risk of genetic discrimination; and personal ownership of genomic data. Members distinguished between indirect benefits to future generations and individual risk to research participants. Feedback was used to revise the recruitment and consent materials. Results highlight tensions reported between the public’s support for genomic research and concerns with genomic information in the medical record and its use in medical decision-making.
Humanism and professionalism education for pediatric hematology‐oncology fellows: A model for pediatric subspecialty training
Kesselheim, Jennifer C. , Atlas, Mark, Adams, Denise M. , Aygün, Banu , Barfield, Ray, Eisenman, Kristen, Fulbright, Joy M. , Garvey, Katharine C. , Kersun, Leslie S. , Rao, Amulya Nageswara, Reilly, Anne, Sharma, Mukta , Shereck, Evan , Wang, Michael , Watt, Tanya , Leavey, Patrick J. , Nageswara Rao, Amulya, Rao, Amulya A. Nageswara , Leavey, Patrick

Pediatric Blood & Cancer | October 12, 2014 | Volume: 62 | Issue: 2 | Pages: 335-340

10.1002/pbc.25253 | PMID 25307425 Get It

BackgroundHumanism and professionalism are virtues intrinsic to the practice of medicine, for which we lack a standard, evidence‐based approach for teaching and evaluation. Pediatric hematology‐oncology (PHO) fellowship training brings new and significant stressors, making it an attractive setting for innovation in humanism and professionalism training.ProcedureWe electronically surveyed a national sample of PHO fellows to identify fellows' educational needs in humanism and professionalism. Next, we developed a case‐based, faculty‐facilitated discussion curriculum to teach this content within pilot fellowship programs. We assessed whether fellowships would decide to offer the curriculum, feasibility of administering the curriculum, and satisfaction of fellow and faculty participants.ResultsSurveys were completed by 187 fellows (35%). A minority (29%) reported that their training program offers a formal curriculum in humanism and/or professionalism. A majority desires more formal teaching on balancing clinical practice and research (85%), coping with death/dying (85%), bereavement (78%), balancing work and personal life (75%), navigating challenging relationships with patients (74%), and depression/burn out (71%). These six topics were condensed into four case‐based modules, which proved feasible to deliver at all pilot sites. Ten fellowship programs agreed to administer the novel curriculum. The majority (90%) of responding fellows and faculty reported the sessions touched on issues important for training, stimulated reflective communication, and were valuable.ConclusionsPediatric hematology‐oncology fellows identify numerous gaps in their training related to humanism and professionalism. This curriculum offers an opportunity to systematically address these educational needs and can serve as a model for wider implementation. Pediatr Blood Cancer 2015;62:335–340. © 2014 Wiley Periodicals, Inc.
Comparative Effectiveness of Carotid Revascularization Therapies
McDonald, Robert J. , Therneau, Terry M. , Kallmes, David F. , Cloft, Harry J. , McDonald, Jennifer S. , Lanzino, Giuseppe

Stroke | October 10, 2014 | Volume: 45 | Issue: 11 | Pages: 3311-3319

10.1161/strokeaha.114.006323 | PMID 25300973 Get It

Background and Purpose— Clinical equipoise of carotid revascularization therapies remains controversial. We sought to determine whether adverse outcomes after carotid endarterectomy (CEA) or carotid angioplasty and stenting (CAS) were similar using propensity score–matched analysis of retrospective data from a large hospital discharge database. Methods— All CEA and CAS cases were identified from the 2006 to 2011 Premier Perspective Database and subjected to 1:1 propensity score matching using 33 clinical covariates associated with carotid revascularization. A primary composite end point of peri- or postoperative mortality, stroke, or acute myocardial infarction and a modified composite end point excluding acute myocardial infarction were used to compare our findings with recent prospective controlled trials. Multivariate regression and Cox-proportional hazard ratio survival analysis were performed to compare revascularization therapy outcomes. Results— After 1:1 propensity score matching, 24 004 (12 002 CEA and CAS) asymptomatic and 3506 (1753 CEA and CAS) symptomatic procedures were included. The risk of the primary composite end point was significantly higher after CAS than CEA in both asymptomatic (odds ratio, 1.40 [1.19–1.65]; P <0.0001) and symptomatic (odds ratio=2.31 [1.78–3.00]; P <0.0001) presentations, irrespective of age ( P =0.28) or sex ( P =0.35). Similar findings were observed using the modified composite end point for both asymptomatic (odds ratio, 1.49 [1.25–1.78]; P <0.0001) and symptomatic (odds ratio, 3.02 [2.25–4.07]; P <0.0001) presentations. Acute myocardial infarction risk was not significantly different between revascularization therapies, regardless of clinical presentation ( P =0.71 and 0.24). Conclusions— Among individuals undergoing carotid artery revascularization from a large sample of US hospitals, CAS was associated with higher risk of perioperative mortality, stroke, and unfavorable discharges compared with CEA for all ages and clinical presentations.